舒泰神：“注射用STSP-0601”药品后续是否进入优先审评程序仍存在诸多不确定性

Core Viewpoint - The company, Shuyou Shen, has announced that there is significant uncertainty regarding whether its drug "STSP-0601" will enter the priority review process after the public notice period ends [1] Group 1: Stock Performance - The company's stock has experienced a significant abnormal fluctuation, with a cumulative price deviation of over 100% in the last ten trading days and over 200% in the last thirty trading days [1] Group 2: Drug Approval Process - The drug "STSP-0601," developed by the company's subsidiary Jiangsu Beijitai Biotechnology Co., is currently in the public notice period, which will end on June 3, 2025 [1] - There is high market attention on the information regarding the drug's application for priority review as published on the National Medical Products Administration (NMPA) website [1] - The company emphasizes that there are many uncertainties regarding whether the drug will proceed to the priority review process after the public notice period [1]